|Day Low/High||40.21 / 41.01|
|52 Wk Low/High||32.69 / 41.77|
AstraZencea shares topped London's FTSE 100 Monday after better-than-expected results in a key lung cancer treatment trial.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced the full progression-free survival (PFS) data from a planned interim analysis of the investigational Phase III PACIFIC trial.
AstraZeneca today announced the full results of the Phase III FLAURA trial, which support TAGRISSO ®'s (osimertinib) clear potential as a new standard of care (SoC) in the 1st-line treatment of adult patients with...
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved FASLODEX ® (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal...
AstraZeneca and Merck & Co., Inc.
The drug would be the first such treatment in Europe.
One of the hottest biotech stocks of the last month is selling off.
Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for...
A glimpse of what to expect during Tuesday's pre-market.
Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.
Big volume is hitting AstraZeneca and a breakout trade could trigger soon.
Higher inflation and, in some parts, solid corporate earnings were both factors on Monday.
U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an...
AstraZeneca's Imfinzi gets reprieve after MYSTIC failure
The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.
The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.
Shares lost more than 16% in London trading
The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.
But not all stocks were helping to push the market higher.
Losses at several major index constituents sank markets Thursday.
These stocks were moving big before the market opened.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.